Cargando…
Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic immune thrombocytopenia (cITP). Avatrombopag has shown promising results in regards to efficacy and tolerability, but to our knowledge, there are no rep...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531320/ https://www.ncbi.nlm.nih.gov/pubmed/37754669 http://dx.doi.org/10.3390/hematolrep15030054 |